Avelumab and Axitinib Combination in Adenoid Cystic Carcinoma

• March 29, 2023
• Reading time: 1 minute

On March 10, 2023, Dr. Renata Ferrarotto and colleagues from The University of Texas MD Anderson Cancer Center published the efficacy and safety results of a Phase 2 clinical trial evaluating the combination of Avelumab and Axitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC) in the Journal of Clinical Oncology.

Study Design: This was an open-label, single-arm Phase 2 clinical trial evaluating the combination of Avelumab (an anti-PD-L1 antibody) and Axitinib (a VEGFR inhibitor) in 40 patients with recurrent or metastatic ACC. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.

Clinical Outcomes: In the evaluable population of 28 patients:

• Objective Response Rate (ORR): 18% (exceeding the primary target).
• 6-Month ORR: 14%.
• Median PFS: 7.3 months.
• 6-Month PFS Rate: 57%.
• Median Overall Survival (OS): 16.6 months.

Safety Profile: The most common adverse events reported by patients included fatigue (62%), hypertension (32%), and diarrhea (32%).

Conclusion: Based on the Phase 2 trial results, Dr. Renata Ferrarotto concluded that the combination of Avelumab and Axitinib demonstrated significant activity in recurrent or metastatic adenoid cystic carcinoma, with an ORR of 18% successfully meeting the study's primary objective.

Source: https://ascopubs.org/doi/abs/10.1200/JCO.22.02221

• Discovering the Key to Aggressive Pancreatic Cancer!
• New Immune Enhancers Boosting Cancer Immunotherapy
• Kyoto University Launches iPS Cell Cancer Therapy!

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Pancreatic cancer